Gantenerumab

Entity type image
Type: Product
Name: Gantenerumab
First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports
MorphoSys AG
MorphoSys AG

GlaxoSmithKline grabs PhII rheumatoid arthritis drug in $579M MorphoSys deal

GlaxoSmithKline ($GSK) has stepped up with a $579 million deal to partner on a mid-stage rheumatoid arthritis therapy developed by Germany's MorphoSys. GSK is paying about $29.25 million of that upfront and will take over all further R&D and commercialization ... [Published FierceBiotech - Jun 03 2013]
First reported Apr 14 2013 - Updated Apr 14 2013 - 1 reports
Roche Holding AG
Roche Holding AG

Roche Holding Earnings Call Insights: Pipeline Details and Kadcyla Outlook

Roche Holding  (RHHBY) recently reported its first quarter earnings and discussed the following topics in its earnings conference call. Pipeline Details Timothy Anderson – Sanford C. Bernstein & Co., LLC: My questions, all have to do with the pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013]

Quotes

"This transaction is a major milestone for MorphoSys, "commented the German firm's chief executive Simon Moroney." We hope this alliance will result in a significant return on investment for the MOR103 program and to become a major value driver for MorphoSys."
GSK taps MorphoSys for rheumatoid arthritis candidate [Published Pharma Times - Jun 04 2013]
"This pioneering trial is one of the most important global studies in the early treatment of Alzheimer's disease that has ever been undertaken. Cogstate is very proud to be supporting this study. Our involvement is an important validation from the global scientific community of the role the tests in our battery can play in the detection of the subtle changes in cognition that can be indicative of the earliest signs of dementia" said Brad O'Connor, Chief Executive Officer of Cogstate
Cogstate selected for pioneering Alzheimer's disease preventation trial [Published Noodls - May 23 2013]
...Seamus Fernandez, of Leerink Swann, gave solanezumab a 30 percent to 50 percent chance of earning $5 billion in sales in 2022, "despite evidence giving a modest signal of cognitive benefit at 18 months."
Pharm Exec's 2013 Pipeline Report [Published Pharmaceutical Executive - Nov 20 2012]

More Content

All (8) | News (6) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
GSK taps MorphoSys for rheumatoid arthritis can... [Published Pharma Times - Jun 04 2013]
GlaxoSmithKline grabs PhII rheumatoid arthritis... [Published FierceBiotech - Jun 03 2013]
Cogstate selected for pioneering Alzheimer's di... [Published Noodls - May 23 2013]
First Alzheimer’s Prevention Trial in Full Swing [Published I Am Biotech - Apr 23 2013]
Roche Holding Earnings Call Insights: Pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013]
Pharm Exec's 2013 Pipeline Report [Published Pharmaceutical Executive - Nov 20 2012]
Investigational drugs, Gantenerumab and Solanez... [Published PharmaBiz - Oct 12 2012]
Roche to strengthen pipeline with 72 new molecu... [Published PharmaBiz - Sep 05 2012]
1
In Focus
  •  
Daniel O'Day, Alan Hippe, Joanne Knight, [more]
  •  
Roche Holding AG, MorphoSys AG, Eli Lilly & Company, [more]
  •  
Washington University School of Medicine, National institutes of Health, National Institute On Aging, [more]
  •  
Alzheimer's Disease, investigational, Phase II, [more]
  •  
Solanezumab, Kadcyla, Perjeta, [more]
  •  
South San Francisco (United States), Medellin, London
  •  
United States, Colombia, Australia, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
Banking & Financial Services, Health, Pharma & Biotech
PharmaBiz, Wall St. Cheat Sheet, FierceBiotech, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
First Alzheimer’s Prevention Trial in Full Swing [Published I Am Biotech - Apr 23 2013]
Double-blind, placebo-controlled study is investigating an anti-amyloid therapy. BIOtechNOW delves into the current state of Alzheimer’s research with today’s feature on prevention trials. Yesterday, we wrote about regulatory challenges in approving ...
Roche Holding Earnings Call Insights: Pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013]
Roche Holding  (RHHBY) recently reported its first quarter earnings and discussed the following topics in its earnings conference call. Pipeline Details Timothy Anderson – Sanford C. Bernstein & Co., LLC: My questions, all have to do with the pipeline ...
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.